All In Biotech

Drug Trial Radar · NCT07062965

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Aug 5, 2025

Primary completion

Jul 22, 2027

Study completion Nov 4, 2030

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jul 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called receptors that bind to hormones like estrogen and progesterone (female sex hormones). These hormones can promote the growth of cancer cells. HER2-negative describes cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Cancer cells that are HER2-negative may grow more slowly and are less likely to recur (come back) or spread to other parts of the body than cancer cells that have a large amount of HER2 on their surface. Advanced cancer is a term that is often used to describe cancer that is unlikely to be cured. Metastatic cancer is the type where the cancer cells spread from one part of the body to another. This study is seeking for participants whose breast cancer has gotten worsen after receiving cyclin dependent kinase (CDK) 4/6 inhibitor-based therapy. Half of participants in this study will receive their usual study treatment, everolimus with endocrine therapy (either exemestane or fulvestrant) for HR-positive/HER2-negative advanced or metastatic breast cancer (A/mBC). The study doctor will discuss which hormone therapy is right for the participant before treatment begins. PF-07248144 is a tablet that will be taken by mouth at home every day in a 28-day cycle. Fulvestrant will be given as two injections (one injection in the buttock) at visits to the study clinic. Everolimus and exemestane are also tablets and will be taken by mouth at home every day in a 28-day cycle. The study will compare the experiences of people receiving PF-07248144 in combination with fulvestrant to those of the people who do not. This will help see if PF-07248144 in combination with fulvestrant is safe and effective.

Conditions

  • Breast Cancer

Interventions

  • PF-07248144Drug

    KAT6 inhibitor

  • FulvestrantDrug

    Endocrine therapy

  • EverolimusDrug

    mTOR inhibitor

  • ExemestaneDrug

    Endocrine therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) as determined by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: From the date of randomization until disease progression or death due to any cause (up to approximately 2 years)

Locations

433 sites in 31 countries. Site status is shown where the registry gives one.

  • Alaska Oncology and Hematology, LLC

    Anchorage, Alaska · Recruiting

  • Ironwood Cancer & Research Centers

    Chandler, Arizona · Recruiting

  • Banner Gateway Medical Center

    Gilbert, Arizona · Recruiting

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • Ironwood Cancer & Research Centers

    Gilbert, Arizona · Recruiting

  • Ironwood Cancer & Research Centers

    Glendale, Arizona · Recruiting

  • Ironwood Cancer & Research Centers

    Goodyear, Arizona · Recruiting

  • Ironwood Cancer & Research Centers

    Mesa, Arizona · Recruiting

  • Ironwood Cancer & Research Centers

    Mesa, Arizona · Recruiting

  • Ironwood Cancer & Research Centers

    Phoenix, Arizona · Recruiting

  • Ironwood Cancer & Research Centers

    Scottsdale, Arizona · Recruiting

  • Highlands Oncology Group, PA

    Fayetteville, Arkansas · Recruiting

  • Highlands Oncology Group, PA

    Rogers, Arkansas · Recruiting

  • Highlands Oncology Group, PA

    Springdale, Arkansas · Recruiting

  • Oncura Health - Anaheim

    Anaheim, California · Recruiting

  • Ventura County Hematology Oncology Specialists

    Camarillo, California · Recruiting

  • Oncura Health - Fountain Valley

    Fountain Valley, California · Recruiting

  • Oncura Health - Corporate (Central IDS & Regulatory Only)

    Glendale, California · Recruiting

  • Oncura Health - Good Samaritan

    Los Angeles, California · Recruiting

  • Dr. Karandeep Singh MD

    Oxnard, California · Recruiting

  • Rolling Oaks Radiology - Oxnard

    Oxnard, California · Recruiting

  • Ventura County Hematology Oncology Specialists

    Oxnard, California · Recruiting

  • Rolling Oaks Radiology North Solar

    Oxnard, California · Recruiting

  • Clinical and Translational Research Unit (CTRU)

    Palo Alto, California · Recruiting

  • Stanford Cancer Center

    Palo Alto, California · Recruiting

  • Stanford Women's Cancer Center

    Palo Alto, California · Recruiting

  • Sansum Clinic

    Santa Barbara, California · Recruiting

  • Sansum Clinic

    Solvang, California · Recruiting

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California · Recruiting

  • Torrance Memorial Physician Network - Cancer Care

    Torrance, California · Recruiting

  • Torrance Memorial Physician Network-Cancer Care

    Torrance, California · Recruiting

  • Harbor-UCLA Medical Center

    Torrance, California · Recruiting

  • Oncura Health - Valley Presbyterian

    Van Nuys, California · Recruiting

  • Ventura County Hematology Oncology Specialists

    Ventura, California · Recruiting

  • Rocky Mountain Cancer Centers LLP

    Aurora, Colorado · Recruiting

  • Rocky Mountain Cancer Centers LLP

    Boulder, Colorado · Recruiting

  • Rocky Mountain Cancer Centers LLP

    Centennial, Colorado · Recruiting

  • Rocky Mountain Cancer Centers LLP

    Colorado Springs, Colorado · Recruiting

  • Rocky Mountain Cancer Centers LLP

    Colorado Springs, Colorado · Recruiting

  • Rocky Mountain Cancer Centers LLP

    Denver, Colorado · Recruiting

Showing 40 of 433 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.